Alumis’ lead drug candidate, ESK-001, is a Tyrosine Kinase 2 (TYK2) inhibitor currently in Phase 3 trials for moderate ... fruquintinib), a selective oral inhibitor of vascular endothelial growth ...

If you want to know what to expect from the Nintendo Switch 2 then we're here to help. We've rounded-up all the latest rumours on Nintendo's next console, including leaks on the Switch 2 release ...

After antibody-drug conjugate (ADC) specialist Seagen was sold to Pfizer last year for a whopping $43 billion, former CEO David Epstein said he was looking to “hopefully make new drugs somewhere ...